Munya Dimairo

Senior Research Fellow. Statistician. Novel trial methods. Former Wellcome Trust & NIHR DR fellow. Views are my own. RT≠ENDORSEMENT 🇿🇼 🇬🇧

[Munya Dimairo @mdimairo]

Canner (1983) ... “decision-making in clinical trials is complicated & often protracted... no single statistical decision rule or procedure can take the place of well-reasoned consideration of all aspects of the data by a group of concerned, competent, & experienced persons...”

[The Lancet @TheLancet]

Stopping GLP-1 treatment linked to twice the risk of heart attack, stroke or death compared with continuing, in people with type 2 diabetes and no cardiovascular disease, according to a new study.

Find out more in @LancetRH_Europe: https://t.co/iNJmDhOPAU

[JAMA @JAMA_current]

💬 Viewpoint by Jay Lusk, MD, MBA, Robert Califf, MD, Ann Marie Navar, MD, PhD, and Emily O’Brien, PhD: Public betting on ongoing #ClinicalTrials and FDA regulatory reviews may threaten trial integrity by introducing financially incentivized signals while follow-up data are still being generated.

Such markets could affect participant retention, reporting, and blinding, with implications for research ethics and evidence validity.

https://t.co/km4wDNYWsR

[House Judiciary Dems @HouseJudiciary]

🚨BREAKING: Judiciary Democrats’ report details mounting evidence linking Trump to Epstein’s criminal activities and DOJ’s cover-up; specific accounts involving 11 women provide more evidence of potential sex crimes.

https://t.co/jXKU20sJN0

[Mark Allen @pistol147]

I do these every morning with a cup of tea out of my positive mindset cup. Been doing this for 2 months now. You don’t have to believe it all at the start!!! It’ll come

[Shaun Lintern @ShaunLintern]

🚨 EXC: Nottingham hospital launches urgent investigation into hip fracture deaths as its mortality rate hits 50% more than national average - the problem is linked to long delays for emergency surgery according to internal documents.

Full story: https://t.co/928lpPWjBX

[Netana Markovitz, MD @NetanaMarkovitz]

This one's for you, dad. @NEJM https://t.co/BzRqH1ZfAP

[The Lancet @TheLancet]

Randomised controlled trials (RCTs) remain the most reliable method for controlling confounding and selection bias when evaluating interventions for clinical use.

A new Comment explores the need for more head-to-head RCTs comparing treatments already in common use: https://t.co/CUC5rlHuD3

[Konstantinos I. Bougioukas @Bugiukas]

🎉 Delighted to finally hold the physical copy of my book, Practical Statistics in Medicine with R: Understanding Fundamental Concepts through Examples.
📓 For orders: https://t.co/pjabfi8e07

[Dan Neidle @DanNeidle]

Most tax calculators tell you how much tax you pay *now*. Ours also shows how much tax you'll pay on your next £1. Your marginal rate.

We'll be publishing straight after the Budget. But here's a preview - I'd love to get feedback.

https://t.co/N1iNsGteTy

[Get Wild 🐦 🦋 🐝 🍃 @mitchellsnik]

Have you ever seen a waterfall going up? 🌊🌬️
Kinder Downfall in the Peak District on a windy day When the winds hit the plateau, they blow the falling water straight back up over the cliffs, creating this unbelievable upside-down waterfall effect.
#KinderDownfall #PeakDistrict

[Munya Dimairo @mdimairo]

@dondo_comfort Bless you all 👏🏾🙏🏾

[Munya Dimairo @mdimairo]

Emergency pack shaping up!

[Ali Max Erturk @erturklab]

The UK launched the AI Biosecurity Lab: £100M public funding plus up to £200M from OpenAI and Anthropic, to spot biological threats earlier and speed up vaccines and treatments.

Europe has world-class biology. Let's put frontier AI right next to it. 👇🏻

https://t.co/SopeNmwy3J

[NEJM @NEJM]

There are currently no approved therapies available for Sjögren’s disease, and trials of multiple biologic and targeted approaches have been negative or inconclusive. Research findings are summarized in a new Quick Take video. https://t.co/TNx7PlAW4a

[STAT @statnews]

An MS treatment from Novartis cut by a third the rates of relapses compared to a standard treatment. https://t.co/bpjYxkwLQ0

[Triad sou. @triadsou]

Estimating Marginal Odds Ratios for Cluster Randomized Trials: The Cluster‐Level GLM. Jennifer A. Thompson, Brennan C. Kahan, Andrew Copas. Statistics in Medicine. https://t.co/PEbbitH2Tl

[National Institute for Health and Care Research @NIHRresearch]

📣 We’re looking for a Chair for our Invention for Innovation (i4i) Product Development Awards (PDA) Funding Committee!

Are you an experienced medtech or life sciences industry professional with a passion for health innovation? This could be an opportunity to help shape the future of healthcare technology development for the NHS.

As Chair, you will lead one of our i4i funding committees, contribute to the strategic development of the programme and strengthen our links with industry.

Interested? Apply now ➡️ https://t.co/7UrQEXwz7v

⏰ Closes on 23 November 2026

#HealthInnovation #MedTech #LifeSciences #ResearchFunding

[ESMO - Eur. Oncology @myESMO]

#ESMO26: The embargo on LBA1, “INTerpath-001: Phase 3 study of the mRNA-based individualised neoantigen therapy intismeran autogene plus pembrolizumab versus pembrolizumab alone for adjuvant treatment of resected stage IIB-IV melanoma”, has been breached. As the data are now publicly available, ESMO has released the information contained in the abstract and has lifted the embargo on the full dataset.

[FDA Drugs and Biologics @FDADrugs]

Big News! CDER's Accelerating Rare disease Cures (ARC) Program released its 2026 Annual Report, highlighting the Program’s success in advancing rare disease drug development for the ~30M Americans living with a rare disease. Read it here: https://t.co/BV7qFQF3kG

[The BMJ @bmj_latest]

Providing authors of randomised controlled trials with a SPIRIT based template during manuscript revision modestly improved the completeness of reporting in the trial protocols without extending revision times., finds new #BMJResearch
https://t.co/m3kCOrmdz0